Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines

Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines

<p>Abstract</p> <p>Background</p> <p>Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. Given that drug cyto...

Full description

Bibliographic Details
Main Authors: Kulkarni Hemant, Göring Harald H H, Diego Vincent, Cole Shelley, Walder Ken R, Collier Greg R, Blangero John, Carless Melanie A
Format: Article
Language:English
Published: BMC 2012-08-01
Series:BMC Medical Genomics
Subjects:
Chronic myeloid leukemia
Microarray
Toxicity
Gene expression
Imatinib
Omacetaxine
Online Access:http://www.biomedcentral.com/1755-8794/5/37

Internet

http://www.biomedcentral.com/1755-8794/5/37

Similar Items